透过收购事项，集团将取得目标公司的控股权益。预期上目标公司将持续产生收益，而收益主要来源于 在中国提供体检服务。集团认为，目标公司运营的体检中心的营业面积约为3,869平方米，拥有44名员 工，其中主任医师、副主任医师6名，该体检中心将逐步展示其在所属地区行业竞争实力。 集团一直积极于中国拓展医疗服务领域，收购事项符合集团在医疗业务领域拓展策略，也是加强其在医 疗业务分部现有主要业务的机会，并可透过目标公司区域优势与业务基础，实现资源整合与优势互补， 支持集团在中国医疗市场持续拓展。董事相信，收购事项将对集团表现带来协同效应，契合整体发展策 略，并为未来成长提供坚实动力。 格隆汇12月31日丨天元医疗(00557.HK)公告，于2025年12月31日，买方中宁县乐康医疗科技(公司间接 全资附属公司)与卖方一邹从贤及卖方二邹蜜贤订立股权转让协议，据此，根据股权转让协议，卖方一 及卖方二分别以其各自持有的目标股权的法定及实益拥有人的身份有条件出售，买方分别向卖方一及卖 方二有条件收购不附带任何产权负担及第三方权利的目标公司宁夏德尚门诊部60%及10%股权(于交割日 合计占目标公司股权70%)，并连同于交割日该等股 ...

集团一直积极于中国拓展医疗服务领域，收购事项符合集团在医疗业务领域的拓展策略，也是加强其在 医疗业务分部现有主要业务的机会，并可透过目标公司的区域优势与业务基础，实现资源整合与优势互 补，支持集团在中国医疗市场的持续拓展。董事相信，收购事项将对集团表现带来协同效应，契合整体 发展策略，并为未来成长提供坚实动力。 透过收购事项，集团将取得目标公司的控股权益。预期上目标公司将持续产生收益，而收益主要来源于 在中国提供体检服务。集团认为，目标公司运营的体检中心的营业面积约为3,869平方米，拥有44名员 工，其中主任医师、副主任医师6名，该体检中心将逐步展示其在所属地区行业的竞争实力。 天元医疗(00557)公布，于2025年12月31日，该公司间接全资附属中宁县乐康医疗科技有限公司拟向邹 从贤女士和邹蜜贤女士收购宁夏德尚门诊部有限责任公司70%股权，代价为人民币210万元。目标公司 为于中国进行体检业务而设立。 ...

透过收购事项，集团将取得目标公司的控股权益。预期上目标公司将持续产生收益，而收益主要来源于 在中国提供体检服务。集团认为，目标公司运营的体检中心的营业面积约为3,869平方米，拥有44名员 工，其中主任医师、副主任医师6名，该体检中心将逐步展示其在所属地区行业的竞争实力。 集团一直积极于中国拓展医疗服务领域，收购事项符合集团在医疗业务领域的拓展策略，也是加强其在 医疗业务分部现有主要业务的机会，并可透过目标公司的区域优势与业务基础，实现资源整合与优势互 补，支持集团在中国医疗市场的持续拓展。董事相信，收购事项将对集团表现带来协同效应，契合整体 发展策略，并为未来成长提供坚实动力。 智通财经APP讯，天元医疗(00557)公布，于2025年12月31日，该公司间接全资附属中宁县乐康医疗科技 有限公司拟向邹从贤女士和邹蜜贤女士收购宁夏德尚门诊部有限责任公司70%股权，代价为人民币210 万元。目标公司为于中国进行体检业务而设立。 ...

Financial Data and Key Metrics Changes - For Q2 2025, the company reported total revenues of $8.2 million, a decrease compared to 2024 due to the phase-in of the 2024 CMS rate announcement impacting reimbursement for positive PAD patients [27] - The net income for Q2 2025 was $66.9 million, translating to $5.71 per basic share and $5.4 per fully diluted share [29] - The company recorded a net unrealized gain of $83.8 million from the change in fair value of Bitcoin holdings during the second quarter [29] Business Line Data and Key Metrics Changes - The healthcare business generated record cash flow of $24 million in 2024, but faced headwinds in 2025 [11][12] - The company acquired 1,444 Bitcoin in Q2 at a total cost of $149.6 million, with a total of 4,636 Bitcoin valued at $496.9 million as of June 30, 2025 [30] Market Data and Key Metrics Changes - The company held 5,021 Bitcoin valued at approximately $586.2 million as of July 31, 2025, with a cost basis of $476 million, resulting in an unrealized gain of $110 million [13][30] - The Bitcoin yield for the year to date through July 31, 2025, was 31.3%, translating into a Bitcoin dollar gain of $84 million [31] Company Strategy and Development Direction - The company aims to accumulate 10,000 Bitcoin by the end of 2025, 42,000 by the end of 2026, and 105,000 by the end of 2027 [14] - A wholly owned subsidiary, CardioVanta, was formed to focus on early detection of heart failure and cardiac arrhythmia, with plans to seek outside capital [32] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of the healthcare business to generate meaningful cash flow, which will enable further Bitcoin acquisitions [6] - The company believes that the current stock valuation is disconnected from its underlying performance and intrinsic value, indicating a commitment to unlocking value for shareholders [10] Other Important Information - The company has strengthened its Bitcoin team by adding notable figures in the Bitcoin space, enhancing its strategic direction [7] - The company is actively exploring a wide range of financing options to amplify shareholder returns [11] Q&A Session Summary Question: Are there concerns about a potential supply glut of public companies pursuing similar Bitcoin treasury strategies? - Management is not concerned, viewing other companies as peers that accelerate Bitcoin adoption [34] Question: Will there be more regular Bitcoin acquisition announcements? - The company does not plan to make weekly announcements but expects an increase in both regularity and size of announcements over time [36] Question: How does management view the MNAV multiple at which the company trades relative to its peers? - Management explained the two strategies of Bitcoin treasury companies, emphasizing the potential for intelligent leverage to amplify future returns [38][40]